Literature DB >> 18072317

Corporate colonization of health activism? Irish health advocacy organizations' modes of engagement with pharmaceutical corporations.

Orla O'Donovan1.   

Abstract

This article is based on a study that aimed to shed light on the "cultures of action" of Irish health advocacy organizations, and particularly their modes of engagement with pharmaceutical corporations. Debates about what some interpret as the "corporate colonization" of health activism provide the backdrop for the analysis. The empirical dimension of the study involved a survey of 112 organizations and in-depth study of a small number of organizations that manifest diverse modes of engagement with the pharmaceutical industry. The varying modes of interaction are plotted along a continuum and characterized as corporatist, cautious cooperation, and confrontational. Evidence is presented of a strong and growing cultural tendency in Irish health advocacy organizations to frame pharmaceutical corporations as allies in their quests for better health. The analysis of four constitutive dimensions of organizations' cultures of action can reveal the legitimating logics underlying their diverging positions around pharmaceutical industry sponsorship. While the research shows that pharmaceutical corporations have largely succeeded in defining themselves as a philanthropic force and rightful players in Irish health activism, it cautions against a simplistic conclusion that this is evidence of corporate colonization.

Mesh:

Substances:

Year:  2007        PMID: 18072317     DOI: 10.2190/HS.37.4.h

Source DB:  PubMed          Journal:  Int J Health Serv        ISSN: 0020-7314            Impact factor:   1.663


  12 in total

1.  Should patient groups accept money from drug companies? No.

Authors:  Barbara Mintzes
Journal:  BMJ       Date:  2007-05-05

2.  Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices.

Authors:  Sheila M Rothman; Victoria H Raveis; Anne Friedman; David J Rothman
Journal:  Am J Public Health       Date:  2011-01-13       Impact factor: 9.308

3.  Assessing stakeholder opinion on relations between cancer patient groups and pharmaceutical companies in Europe.

Authors:  Susanna Leto di Priolo; Andras Fehervary; Phil Riggins; Kathy Redmond
Journal:  Patient       Date:  2012       Impact factor: 3.883

4.  Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?

Authors:  David Hughes; Bryn Williams-Jones
Journal:  Healthc Policy       Date:  2013-08

5.  Legislating Patient Representation: A Comparison Between Austrian and German Regulations on Self-Help Organizations as Patient Representatives.

Authors:  Daniela Rojatz; Julia Fischer; Hester Van de Bovenkamp
Journal:  J Bioeth Inq       Date:  2018-07-02       Impact factor: 1.352

6.  Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey.

Authors:  Cinzia Colombo; Paola Mosconi; Walter Villani; Silvio Garattini
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

7.  Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?

Authors:  Dylan Pashley; Piotr Ozieranski; Shai Mulinari
Journal:  Int J Health Serv       Date:  2022-03-01       Impact factor: 1.851

8.  Financial relationships between patient and consumer representatives and the health industry: A systematic review.

Authors:  Joanne Khabsa; Aline Semaan; Amena El-Harakeh; Assem M Khamis; Serena Obeid; Hussein A Noureldine; Elie A Akl
Journal:  Health Expect       Date:  2019-12-19       Impact factor: 3.377

9.  Industry funding of patient and health consumer organisations: systematic review with meta-analysis.

Authors:  Alice Fabbri; Lisa Parker; Cinzia Colombo; Paola Mosconi; Giussy Barbara; Maria Pina Frattaruolo; Edith Lau; Cynthia M Kroeger; Carole Lunny; Douglas M Salzwedel; Barbara Mintzes
Journal:  BMJ       Date:  2020-01-22

10.  "Asset exchange"-interactions between patient groups and pharmaceutical industry: Australian qualitative study.

Authors:  Lisa Parker; Alice Fabbri; Quinn Grundy; Barbara Mintzes; Lisa Bero
Journal:  BMJ       Date:  2019-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.